• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肿瘤环境中调节性T细胞的募集与扩增——如何靶向作用于它们?

Recruitment and Expansion of Tregs Cells in the Tumor Environment-How to Target Them?

作者信息

Cinier Justine, Hubert Margaux, Besson Laurie, Di Roio Anthony, Rodriguez Céline, Lombardi Vincent, Caux Christophe, Ménétrier-Caux Christine

机构信息

University of Lyon, Claude Bernard Lyon 1 University, INSERM U-1052, CNRS 5286 Centre Léon Bérard, Cancer Research Center of Lyon (CRCL), 69008 Lyon, France.

Institut de Recherche Servier, 125 Chemin de Ronde, 78290 Croissy-sur-Seine, France.

出版信息

Cancers (Basel). 2021 Apr 13;13(8):1850. doi: 10.3390/cancers13081850.

DOI:10.3390/cancers13081850
PMID:33924428
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8069615/
Abstract

Regulatory T cells (Tregs) are present in a large majority of solid tumors and are mainly associated with a poor prognosis, as their major function is to inhibit the antitumor immune response contributing to immunosuppression. In this review, we will investigate the mechanisms involved in the recruitment, amplification and stability of Tregs in the tumor microenvironment (TME). We will also review the strategies currently developed to inhibit Tregs' deleterious impact in the TME by either inhibiting their recruitment, blocking their expansion, favoring their plastic transformation into other CD4 T-cell subsets, blocking their suppressive function or depleting them specifically in the TME to avoid severe deleterious effects associated with Treg neutralization/depletion in the periphery and normal tissues.

摘要

调节性T细胞(Tregs)在绝大多数实体瘤中都存在,并且主要与预后不良相关,因为它们的主要功能是抑制抗肿瘤免疫反应,从而导致免疫抑制。在本综述中,我们将研究肿瘤微环境(TME)中Tregs的募集、扩增和稳定性所涉及的机制。我们还将综述目前开发的策略,这些策略通过抑制Tregs的募集、阻止其扩增、促进其向其他CD4 T细胞亚群的可塑性转变、阻断其抑制功能或在TME中特异性清除它们,来抑制Tregs在TME中的有害影响,以避免与外周和正常组织中Treg中和/清除相关的严重有害影响。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0dba/8069615/448db011e1c7/cancers-13-01850-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0dba/8069615/2ec654ef24be/cancers-13-01850-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0dba/8069615/57eb02889465/cancers-13-01850-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0dba/8069615/f05413fb1718/cancers-13-01850-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0dba/8069615/448db011e1c7/cancers-13-01850-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0dba/8069615/2ec654ef24be/cancers-13-01850-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0dba/8069615/57eb02889465/cancers-13-01850-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0dba/8069615/f05413fb1718/cancers-13-01850-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0dba/8069615/448db011e1c7/cancers-13-01850-g004.jpg

相似文献

1
Recruitment and Expansion of Tregs Cells in the Tumor Environment-How to Target Them?肿瘤环境中调节性T细胞的募集与扩增——如何靶向作用于它们?
Cancers (Basel). 2021 Apr 13;13(8):1850. doi: 10.3390/cancers13081850.
2
Targeting regulatory T cells for immunotherapy in melanoma.靶向调节性T细胞用于黑色素瘤的免疫治疗。
Mol Biomed. 2021;2(1):11. doi: 10.1186/s43556-021-00038-z. Epub 2021 Apr 19.
3
Treg Fragility: A Prerequisite for Effective Antitumor Immunity?调节性 T 细胞脆弱性:抗肿瘤免疫的必要条件?
Cancer Immunol Res. 2018 Aug;6(8):882-887. doi: 10.1158/2326-6066.CIR-18-0066.
4
FoxP3 T regulatory cells in cancer: Prognostic biomarkers and therapeutic targets.FoxP3+ T 调节性细胞在癌症中的作用:预后生物标志物和治疗靶点。
Cancer Lett. 2020 Oct 10;490:174-185. doi: 10.1016/j.canlet.2020.07.022. Epub 2020 Jul 25.
5
Treg-mediated acquired resistance to immune checkpoint inhibitors.调节性 T 细胞介导的免疫检查点抑制剂获得性耐药。
Cancer Lett. 2019 Aug 10;457:168-179. doi: 10.1016/j.canlet.2019.05.003. Epub 2019 May 9.
6
Immune Checkpoints in Circulating and Tumor-Infiltrating CD4 T Cell Subsets in Colorectal Cancer Patients.结直肠癌患者循环和肿瘤浸润 CD4 T 细胞亚群中的免疫检查点。
Front Immunol. 2019 Dec 17;10:2936. doi: 10.3389/fimmu.2019.02936. eCollection 2019.
7
Blocking the recruitment of naive CD4 T cells reverses immunosuppression in breast cancer.阻断初始CD4 T细胞的募集可逆转乳腺癌中的免疫抑制。
Cell Res. 2017 Apr;27(4):461-482. doi: 10.1038/cr.2017.34. Epub 2017 Mar 14.
8
Tumor microenvironment dictates regulatory T cell phenotype: Upregulated immune checkpoints reinforce suppressive function.肿瘤微环境决定调节性 T 细胞表型:上调的免疫检查点增强抑制功能。
J Immunother Cancer. 2019 Dec 4;7(1):339. doi: 10.1186/s40425-019-0785-8.
9
Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells.癌症治疗中的免疫检查点抑制剂:以 T 调节细胞为重点。
Immunol Cell Biol. 2018 Jan;96(1):21-33. doi: 10.1111/imcb.1003. Epub 2017 Nov 17.
10
Nonhuman Primate Testing of the Impact of Different Regulatory T Cell Depletion Strategies on Reactivation and Clearance of Latent Simian Immunodeficiency Virus.非人灵长类动物试验研究不同调节性 T 细胞耗竭策略对潜伏性猴免疫缺陷病毒再激活和清除的影响
J Virol. 2020 Sep 15;94(19). doi: 10.1128/JVI.00533-20.

引用本文的文献

1
Stereotactic radiotherapy for brain metastases of non-small cell lung cancer: A comprehensive review.非小细胞肺癌脑转移的立体定向放射治疗:一项综述
World J Radiol. 2025 Aug 28;17(8):111076. doi: 10.4329/wjr.v17.i8.111076.
2
Biomechanics of the tumor extracellular matrix and regulatory T cells: regulatory mechanisms and potential therapeutic targets.肿瘤细胞外基质与调节性T细胞的生物力学:调节机制与潜在治疗靶点
Cell Commun Signal. 2025 Aug 21;23(1):375. doi: 10.1186/s12964-025-02380-z.
3
Cancer Vaccination and Immune-Based Approaches in Pancreatic Cancer.

本文引用的文献

1
Fc-Optimized Anti-CCR8 Antibody Depletes Regulatory T Cells in Human Tumor Models.Fc 优化的抗 CCR8 抗体在人类肿瘤模型中耗竭调节性 T 细胞。
Cancer Res. 2021 Jun 1;81(11):2983-2994. doi: 10.1158/0008-5472.CAN-20-3585. Epub 2021 Mar 23.
2
Stress-induced upregulation of TNFSF4 in cancer-associated fibroblast facilitates chemoresistance of lung adenocarcinoma through inhibiting apoptosis of tumor cells.应激诱导的肿瘤相关成纤维细胞中 TNFSF4 的上调通过抑制肿瘤细胞凋亡促进肺腺癌的化疗耐药性。
Cancer Lett. 2021 Jan 28;497:212-220. doi: 10.1016/j.canlet.2020.10.032. Epub 2020 Oct 24.
3
CC Chemokines in a Tumor: A Review of Pro-Cancer and Anti-Cancer Properties of Receptors CCR5, CCR6, CCR7, CCR8, CCR9, and CCR10 Ligands.
胰腺癌的癌症疫苗接种及基于免疫的治疗方法
Cancers (Basel). 2025 Jul 15;17(14):2356. doi: 10.3390/cancers17142356.
4
Unveiling the power of plumbagin: revitalizing exhausted T cells to combat tongue cancer.揭示白花丹醌的力量:重振耗竭的T细胞以对抗舌癌。
Cancer Cell Int. 2025 Jul 19;25(1):271. doi: 10.1186/s12935-025-03892-x.
5
Advancing CAR-based cell therapies for solid tumours: challenges, therapeutic strategies, and perspectives.推进基于嵌合抗原受体(CAR)的实体瘤细胞疗法:挑战、治疗策略及展望
Mol Cancer. 2025 Jul 7;24(1):191. doi: 10.1186/s12943-025-02386-8.
6
The role of T-helper and T regulatory cells in driving neutrophilic and eosinophilic inflammation in bronchiectasis.辅助性T细胞和调节性T细胞在支气管扩张症中引发嗜中性粒细胞性和嗜酸性粒细胞性炎症方面的作用。
Front Immunol. 2025 Jun 16;16:1598257. doi: 10.3389/fimmu.2025.1598257. eCollection 2025.
7
Metabolism and Immune Suppressive Response in Liver Cancer.肝癌中的代谢与免疫抑制反应
Biomedicines. 2025 Jun 13;13(6):1461. doi: 10.3390/biomedicines13061461.
8
Immunosuppressive tumor microenvironment in pancreatic cancer: mechanisms and therapeutic targets.胰腺癌中的免疫抑制性肿瘤微环境:机制与治疗靶点
Front Immunol. 2025 May 15;16:1582305. doi: 10.3389/fimmu.2025.1582305. eCollection 2025.
9
Targeting HIF-2α in glioblastoma reshapes the immune infiltrate and enhances response to immune checkpoint blockade.靶向胶质母细胞瘤中的低氧诱导因子-2α可重塑免疫浸润并增强对免疫检查点阻断的反应。
Cell Mol Life Sci. 2025 Mar 17;82(1):119. doi: 10.1007/s00018-025-05642-8.
10
Macrophage-derived lncRNAs in cancer: regulators of tumor progression and therapeutic targets.癌症中巨噬细胞衍生的长链非编码RNA:肿瘤进展的调节因子和治疗靶点。
Med Oncol. 2025 Mar 6;42(4):91. doi: 10.1007/s12032-025-02643-2.
肿瘤中的 CC 趋化因子:受体 CCR5、CCR6、CCR7、CCR8、CCR9 和 CCR10 配体的促癌和抗癌特性综述。
Int J Mol Sci. 2020 Oct 15;21(20):7619. doi: 10.3390/ijms21207619.
4
The CCL20-CCR6 Axis in Cancer Progression.CCL20-CCR6 轴在癌症进展中的作用。
Int J Mol Sci. 2020 Jul 22;21(15):5186. doi: 10.3390/ijms21155186.
5
Novel Piperidinyl-Azetidines as Potent and Selective CCR4 Antagonists Elicit Antitumor Response as a Single Agent and in Combination with Checkpoint Inhibitors.新型哌啶基氮杂环丁烷类化合物作为强效和选择性的 CCR4 拮抗剂,单药或与检查点抑制剂联合使用可引发抗肿瘤反应。
J Med Chem. 2020 Aug 13;63(15):8584-8607. doi: 10.1021/acs.jmedchem.0c00988. Epub 2020 Jul 28.
6
An Oncogenic Alteration Creates a Microenvironment that Promotes Tumor Progression by Conferring a Metabolic Advantage to Regulatory T Cells.致癌改变创造了一种微环境,通过赋予调节性 T 细胞代谢优势来促进肿瘤进展。
Immunity. 2020 Jul 14;53(1):187-203.e8. doi: 10.1016/j.immuni.2020.06.016. Epub 2020 Jul 7.
7
The CCL5/CCR5 Axis in Cancer Progression.癌症进展中的CCL5/CCR5轴
Cancers (Basel). 2020 Jul 2;12(7):1765. doi: 10.3390/cancers12071765.
8
Blockade of PD-1, PD-L1, and TIM-3 Altered Distinct Immune- and Cancer-Related Signaling Pathways in the Transcriptome of Human Breast Cancer Explants.PD-1、PD-L1 和 TIM-3 阻断改变了人乳腺癌外植体转录组中独特的免疫和癌症相关信号通路。
Genes (Basel). 2020 Jun 25;11(6):703. doi: 10.3390/genes11060703.
9
Tumor invasion in draining lymph nodes is associated with Treg accumulation in breast cancer patients.肿瘤在引流淋巴结中的浸润与乳腺癌患者 Treg 细胞的聚集有关。
Nat Commun. 2020 Jun 29;11(1):3272. doi: 10.1038/s41467-020-17046-2.
10
Mogamulizumab in Combination with Durvalumab or Tremelimumab in Patients with Advanced Solid Tumors: A Phase I Study.莫格利珠单抗联合度伐利尤单抗或替西木单抗治疗晚期实体瘤患者的 I 期研究。
Clin Cancer Res. 2020 Sep 1;26(17):4531-4541. doi: 10.1158/1078-0432.CCR-20-0328. Epub 2020 Jun 25.